Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Beginning Cash Balance (2022 - 2024)

Historic Beginning Cash Balance for Summit Therapeutics (SMMT) over the last 3 years, with Q4 2024 value amounting to $75.5 million.

  • Summit Therapeutics' Beginning Cash Balance changed N/A to $75.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $151.0 million, marking a year-over-year increase of 51168.27%. This contributed to the annual value of $100.0 million for FY2024, which is 30508.79% up from last year.
  • According to the latest figures from Q4 2024, Summit Therapeutics' Beginning Cash Balance is $75.5 million.
  • In the past 5 years, Summit Therapeutics' Beginning Cash Balance ranged from a high of $75.5 million in Q3 2024 and a low of $24.7 million during Q1 2023
  • Over the past 3 years, Summit Therapeutics' median Beginning Cash Balance value was $50.2 million (recorded in 2022), while the average stood at $50.2 million.